Sonnet BioTherapeutics Holdings, Inc. (SONN)

NASDAQ: SONN · Real-Time Price · USD

1.560

-0.030 (-1.89%)

Dec 20, 2024, 4:00 PM EST - Market closed

SONN Employees

Sonnet BioTherapeutics Holdings had 12 employees as of September 30, 2023. The number of employees did not change compared to the previous year.

Employees

12

Change (1Y)

n/a

Growth (1Y)

n/a

Revenue / Employee

$1,552

Profits / Employee

-$619,769

Market Cap

4.69M

Employees Chart

Employees History

Date	Employees	Change	Growth
Sep 30, 2023	12	0	-
Sep 30, 2022	12	3	33.33%
Sep 30, 2021	9	0	-
Sep 30, 2020	9	-21	-70.00%
Sep 30, 2019	30	-	-

Related Stocks

Company Name	Employees
Biomerica	64
Sintx Technologies	43
Predictive Oncology	35
Healthcare Triangle	31
FOXO Technologies	29
Galmed Pharmaceuticals	8

Employee Rankings

SONN News

4 days ago - Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
12 days ago - Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
12 days ago - Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial - GlobeNewsWire
17 days ago - Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action - GlobeNewsWire
5 weeks ago - Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment - GlobeNewsWire
6 weeks ago - Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
6 weeks ago - Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates - GlobeNewsWire
2 months ago - Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq - GlobeNewsWire